Skin cancer diagnoses and deaths continue to increase every year. With basal cell carcinoma (BCC) being the most common type of skin cancer diagnoses, establishing protective measurements against it are important. Surprisingly, sunscreen may not be as effective at protecting against basal cell carcinoma as it is for another non-melanoma type of skin cancer: squamous cell carcinoma. This paper aims to identify some differences between the two non-melanoma type cancers to find probable reasons sunscreen may be more effective at protecting against one over the other, as well as to find new solutions to protect against basal cell carcinoma. The results conclude that basal cell carcinoma does have UV-induced pathogenesis, in which case sunscreen is protective; however, it also revealed the need for ingredient studies and more sunscreen efficacy studies to determine other BCC pathogenesis pathways. Lastly, aided by dermatologist interviews, current interventions were established in order to provide greater protection against skin cancer. These include reforming the way commercials portray sunscreen to better educate the public about proper application and re-application, genetic testing for high-risk BCC markers, and an emphasis on sun education to the mothers of children.

This analysis explores what the time needed to harden, and time needed to degrade is of a PLGA bead, as well as whether the size of the needle injecting the bead and the addition of a drug (Vismodegib) may affect these variables. Polymer degradation and hardening are critical to understand for the polymer’s use in clinical settings, as these factors help determine the patients’ and healthcare providers’ use of the drug and estimated treatment time. Based on the literature, it is expected that the natural logarithmic polymer mass degradation forms a linear relationship to time. Polymer hardening was tested by taking video recordings of gelatin plates as they are injected with microneedles and performing RGB analysis on the polymer “beads” created. Our results for the polymer degradation experiments showed that the polymer hardened for all solutions and trials within approximately 1 minute, presenting a small amount of time in which the patient would have to remain motionless in the affected area. Both polymer bead size and drug concentration may have had a modest impact on the hardening time experiments, while bead size may affect the time required for the polymer to degrade. Based on the results, the polymer degradation is expected to last multiple weeks, which may allow for the polymer to be used as a long-term drug delivery system in treatment of basal cell carcinoma.